Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Upregulation of sFRP1 Is More Profound in Female than Male 5xFAD Mice and Positively Associated with Amyloid Pathology
Macyczko, Jesse R. , Wang, Na , Lü, Wenyan, Jeevaratnam, Suren , Shue, Francis , Martens, Yuka A. , Liu, Chia‐Chen , Kanekiyo, Takahisa , Bu, Guojun , Li, Yonghe , Martens, Yuka, Liu, Chia-Chen , Bu, Guojun , Shue, Francis

Mayo Clinic

Journal of Alzheimer's Disease | August 4, 2023 | Volume: 95 | Issue: 2 | Pages: 399-405

10.3233/jad-230218 | PMID 37545238 Get It

The prevalence of Alzheimer’s disease is greater in women, but the underlying mechanisms remain to be elucidated. We herein demonstrated that α-secretase ADAM10 was downregulated and ADAM10 inhibitor sFRP1 was upregulated in 5xFAD mice. While there were no sex effects on ADAM10 protein and sFRP1 mRNA levels, female 5xFAD and age-matched non-transgenic mice exhibited higher levels of sFRP1 protein than corresponding male mice. Importantly, female 5xFAD mice accumulated more Aβ than males, and sFRP1 protein levels were positively associated with Aβ42 levels in 5xFAD mice. Our study suggests that sFRP1 is associated with amyloid pathology in a sex-dependent manner.
Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade
Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Ji, Keven Seung Yong , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , O’Byrne, Jamie, Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Young, Sarah C. , Zenonos, Georgios A. , Zwagerman, Nathan T. , McMillan, Ryan, O'Byrne, Jamie, Peris Celda, Maria, Pinheiro-Neto, Carlos, Patel, Zara , Hwang, Peter H , Choby, Garret , Geltzeiler, Mathew , Almeida, João Paulo , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Snyderman, Carl H , Gompel, Jamie J. Van , Wang, Eric W

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 3, 2023 | Volume: 149 | Issue: 9 | Pages: 837

10.1001/jamaoto.2023.1939 | PMID 37535372 Get It

ImportanceCurrent olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence.ObjectiveThe primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence.Design, Setting, and ParticipantsThis retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers.InterventionStandard-of-care ONB treatment.Main Outcome and MeasuresThe main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction.ResultsA total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18).Conclusions and RelevanceThe study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.
AdvanTIG-105: Phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).
Kim, Sae Hyun , Shiah, Her‐Shyong, Yoon, Harry H. , Zheng, Hao , Zhou, Ziqi , Wang, Ruihua , Lee, Gyeong‐Won , Shim, Byoung Yong , Frentzas, Sophia , Sun, Meili , Clay, Timothy Dudley , Tan, Wei, Ba, Yi

Mayo Clinic

JCO Global Oncology | August 3, 2023 | Volume: 9 | Issue: Supplement_1 | Pages: 31-31

10.1200/go.2023.9.supplement_1.31 Get It

31 Background: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) inhibitor in combination with an anti-programmed cell death protein 1 (PD-1) antibody has shown antitumor activity in solid tumors. AdvanTIG-105 (NCT04047862) is a phase 1/1b open-label study designed to assess the safety and preliminary antitumor activity of OCI, an anti-TIGIT monoclonal antibody (mAb), + TIS, an anti-PD-1 mAb, in pts with unresectable, locally advanced or metastatic solid tumors. In the dose-escalation part, OCI + TIS was well tolerated with preliminary antitumor activity observed, and the recommended phase 2 dose (RP2D) of OCI 900 mg intravenously (IV) every three weeks (Q3W) + TIS 200 mg IV Q3W was established. We report results from the dose-expansion part (GC/GEJC Cohort 9) of the AdvanTIG-105 study. Methods: Eligible pts had histologically/cytologically confirmed stage IV GC/GEJC. Pts were excluded if they had squamous cell, undifferentiated or other histological types of GC, had GC/GEJC with positive HER2 expression, or if they had received any prior therapy for metastatic disease. Pts received either the RP2D of OCI + TIS with oxaliplatin + capecitabine Q3W for 6 cycles (C), followed by maintenance therapy with the RP2D of OCI + TIS, + capecitabine Q3W, or the RP2D of OCI + TIS with cisplatin + 5-fluorouracil Q3W for 6 C. Treatment continued until disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed overall response rate (ORR) per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR) per RECIST v1.1, and safety. Results: As of September 29, 2022, 60 pts with a median age of 61.5 years (range 35-82) were enrolled; 59 were efficacy evaluable. Median study follow-up was 31.1 weeks (range 1.4-78.4). ORR was 50.8% (95% CI: 37.5, 64.1); DCR was 84.7% (95% CI: 73.0, 92.8) with a median DoR of 8.1 months (95% CI: 4.5, not evaluable [NE]). Median PFS was 8.2 months (95% CI: 5.8, NE). In a subgroup analysis, ORR in pts with PD-L1 tumor area positivity (TAP) score ≥5% (n=27) was 59.3% (95% CI: 38.8, 77.6), and 50.0% (95% CI: 30.7, 69.4) in pts with PD-L1 TAP <5% (n=28). All 60 pts reported ≥1 treatment-emergent adverse event (TEAE), the most common being anemia (43.3%) and platelet count decreased (41.7%). In total, 43 pts (71.7%) had ≥grade 3 TEAEs and 28 (46.7%) had serious adverse events. TEAEs leading to discontinuation of TIS and OCI occurred in 5 (8.3%) pts. TEAEs led to death in 2 (3.3%) pts; one event (neutropenic sepsis) was related to chemo, while the other (pulmonary embolism) was not treatment related. Conclusions: OCI 900 mg + TIS 200 mg + chemo was generally well tolerated and showed encouraging antitumor activity in pts with stage IV GC/GEJC. Clinical trial information: NCT04047862 .
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
Berenson, Charles S., Lashner, Bret A., Korman, Louis Y. , Hohmann, Elizabeth , Louie, Thomas , Sims, Matthew , Pardi, Darrell S. , Kraft, Colleen S., Wang, Elaine E. L., Cohen, Stuart H. , Oneto, Caterina , Misra, Bharat , Pullman, John, Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Lee, Christine H. , Pardi, Darrell, McGovern, Barbara H , Deshpande, Abhishek , Kraft, Colleen S. , Feuerstadt, Paul , De, Ananya, Memisoglu, Asli, Lombardi, David A

Mayo Clinic

Clinical Infectious Diseases | August 3, 2023 | Volume: 77 | Issue: 11 | Pages: 1504-1510

10.1093/cid/ciad448 | PMID 37539715 Get It

Abstract Background Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind, placebo-controlled, randomized trial (ECOSPOR III), fecal microbiota spores, live (VOWST, Seres Therapeutics; hereafter “VOS,” formerly SER-109), an oral microbiota therapeutic, significantly reduced the risk of rCDI at week 8. We evaluated the efficacy of VOS compared with placebo in patients with comorbidities and other risk factors for rCDI. Methods Adults with rCDI were randomized to receive VOS or placebo (4 capsules daily for 3 days) following standard-of-care antibiotics. In this post hoc analysis, the rate of rCDI through week 8 was assessed in VOS-treated participants compared with placebo for subgroups including (i) Charlson comorbidity index (CCI) score category (0, 1–2, 3–4, ≥5); (ii) baseline creatinine clearance (&lt;30, 30–50, &gt;50 to 80, or &gt;80 mL/minute); (iii) number of CDI episodes, inclusive of the qualifying episode (3 and ≥4); (iv) exposure to non-CDI-targeted antibiotics after dosing; and (v) acid-suppressing medication use at baseline. Results Of 281 participants screened, 182 were randomized (59.9% female; mean age, 65.5 years). Comorbidities were common with a mean overall baseline age-adjusted CCI score of 4.1 (4.1 in the VOS arm and 4.2 in the placebo arm). Across all subgroups analyzed, VOS-treated participants had a lower relative risk of recurrence compared with placebo. Conclusions In this post hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications, or comorbidities.
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Huamán, Moisés A. , Patel, Bela , Marshall, Christi E., Yarava, Anusha , Heath, Sonya L. , Fukuta, Yuriko , Blair, Janis E. , Spivak, Emily S , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Ram, Malathi , Das, Piyali, Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Laeyendecker, Oliver , Ehrhardt, Stephan , Lau, Bryan , Baksh, Sheriza , Shade, David , Ou, Jiangda , Gniadek, Thomas J. , Ziman, Alyssa , Bloch, Evan M. , Gerber, Jonathan M. , Ziman, Alyssa , Bloch, Evan M , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Laeyendecker, Oliver , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Currier, Judith S. , Broderick, Patrick B., Sutcliffe, Catherine G , Zand, Martin S. , Kassaye, Seble , Wang, Ying , Ford, Daniel E , Pekosz, Andrew , Klein, Sabra L , Casadevall, Arturo , Hanley, Daniel F. , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Transfusion | August 3, 2023 | Volume: 63 | Issue: 9 | Pages: 1639-1648

10.1111/trf.17485 | PMID 37534607 Get It

AbstractBackgroundCOVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.Study Design and MethodsWe analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.ResultsThe combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications.DiscussionOutpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19.
Kounis Syndrome, an Unrecognized Presentation of Perioperative Anaphylaxis in a Transplant Candidate
Hong, Andrew D., Fleissner, Zachary, Campos-Cuellar, Cesar, Wang, R. Doris, Pai, Sher‐Lu , Fleissner, Zachary J., Pai, Sher-Lu , Gonzalez‐Estrada, Alexei , Mao, Shennen A.

Mayo Clinic

Progress in Transplantation | August 3, 2023 | Volume: 33 | Issue: 3 | Pages: 270-271

10.1177/15269248231191485 | PMID 37533329 Get It

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
Sun, Rui , Yan, Binyuan , Li, Hao , Ding, Donglin , Wang, Liguo , Pang, Jun , Ye, Dingwei , Huang, Haojie , Sun, Rui , Wang, Liguo , Huang, Rui , Yan, Binyuan , Pang, Jun , Ding, Donglin , Sun, Rui

Mayo Clinic

Cancer Research | August 1, 2023 | Volume: 83 | Issue: 19 | Pages: 3192-3204

10.1158/0008-5472.can-23-0285 | PMID 37527336 Get It

Abstract Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to improve patient outcomes. Here we demonstrated that acute treatment with the antiandrogen enzalutamide (ENZ) decreased glutathione (GSH) production, increased lipid peroxidation, and induced ferroptosis in prostate cancer cells. Consistently, meta-analysis of transcriptomic data linked the androgen-AR axis to metabolism-related biological processes, including lipid metabolism. The cystine transporter gene SLC7A11 was a key AR target, and full-length AR (AR-FL) transactivated SLC7A11 transcription by directly occupying the SLC7A11 promoter and putative enhancer regions. AR variants (AR-V) preferentially bound the SLC7A11 enhancer and upregulated SLC7A11 expression, thereby conferring resistance to ferroptosis induced by ENZ treatment. However, this effect was abolished following downregulation of AR-Vs using the dual CBP/p300 and BET inhibitor NEO2734. These findings reveal ferroptosis induction as an anticancer mechanism of antiandrogens and SLC7A11 as a direct target gene of AR-FL and AR-Vs. AR-V-mediated SLC7A11 expression represents a mechanism coupling ferroptosis resistance to prostate cancer progression. Significance: Upregulation of SLC7A11 can be induced by androgen receptor variants to inhibit antiandrogen-induced prostate cancer cell ferroptosis and to drive castration resistance in prostate cancer.
Myocardial Fibrosis and Cardiomyopathy Risk: A Genetic Link in the MESA
Shabani, Mahsima , Wang, Min , Jenkins, Gregory D. , Rotter, Jerome I. , Rich, Stephen S. , Batzler, Anthony , Taylor, Kent D. , Mychaleckyj, Josyf C. , Liu, Duan , Lima, João A.C. , Pereira, Naveen L. , Rich, Stephen S , Rotter, Jerome I , Wang, Min , Taylor, Kent D , Liu, Duan

Mayo Clinic

Circulation: Heart Failure | August 1, 2023 | Volume: 16 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.010262 | PMID 37526028 Get It

BACKGROUND: Common genetic variants are associated with risk for hypertrophic cardiomyopathy and dilated cardiomyopathy and with left ventricular (LV) traits. Whether these variants are associated with myocardial fibrosis, an important pathophysiological mediator of cardiomyopathy, is unknown. METHODS: Multi-Ethnic Study of Atherosclerosis participants with T1-mapping cardiac magnetic resonance imaging in-whom extracellular volume was assessed, and genotyping information was available were included (N=1255). Log extracellular volume (%) was regressed on 50 candidate single nucleotide polymorphisms (previously identified to be associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and LV traits) adjusting for age, sex, diabetes, blood pressure, and principal components of ancestry. Ancestry-specific results were pooled by fixed-effect meta-analyses. Gene knockdown experiments were performed in human cardiac fibroblasts. RESULTS: The SMARCB1 rs2186370 intronic variant (minor allele frequency: 0.18 in White and 0.50 in Black participants), previously identified as a risk variant for dilated cardiomyopathy and hypertrophic cardiomyopathy, was significantly associated with increased extracellular volume ( P= 0.0002) after adjusting for confounding clinical variables. The SMARCB1 rs2070458 locus previously associated with increased LV wall thickness and mass was similarly significantly associated with increased extracellular volume ( P= 0.0002). The direction of effect was similar in all 4 ancestry groups, but the effect was strongest in Black participants. The variants are strong expression quantitative loci in human LV tissue and associated with genotype-dependent decreased expression of SMARCB1 ( P= 7.3×10 -22 ). SMARCB1 knockdown in human cardiac fibroblasts resulted in increased TGF (transforming growth factor)-β1–mediated α-smooth muscle actin and collagen expression. CONCLUSIONS: Common genetic variation in SMARCB1 previously associated with risk for cardiomyopathies and increased LV wall thickness is associated with increased cardiac magnetic resonance imaging–based myocardial fibrosis and increased TGF-β1 mediated myocardial fibrosis in vitro. Whether these findings suggest a pathophysiologic link between myocardial fibrosis and cardiomyopathy risk remains to be proven.
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, Aaron R. , Scharschmidt, Thomas J. , Xue, Wei , Gao, Zhengya, Black, Jennifer O. , Choy, Edwin , Fanburg–Smith, Julie C. , Kao, Simon C. , Kayton, Mark L. , Kessel, Sandy, Lim, Ruth , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Parisi, Marguerite T. , Pryma, Daniel A. , Rosen, Mark, Terezakis, Stephanie , Venkatramani, Rajkumar , Zambrano, Eduardo , Wang, Dian , Hawkins, Douglas S. , Black, Jennifer O , Choy, Edwin , Kao, Simon C , Kayton, Mark L , Lim, Ruth , Million, Lynn , Okuno, Scott , Ostrenga, Andrew , Pryma, Daniel A , Randall, Robert Lor , Shulkin, Barry L , Terezakis, Stephanie A , Venkatramani, Rajkumar , Wang, Dian , Hawkins, Douglas S , Spunt, Sheri L , Weiss, Aaron R , Chen, Yen‐Lin , Davis, Jessica L. , Randall, R. Lor , Shulkin, Barry L. , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | July 31, 2023 | Volume: 41 | Issue: 31 | Pages: 4842-4848

10.1200/jco.23.00045 | PMID 37523624 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
Angelica Sinensis Polysaccharide Protects Chondrocytes from Ferroptosis in Osteoarthritis
Yin, Guangrong , Yu, Yunyuan , Wang, Liangliang , Zhou, Baojun , Zhao, Gongying, Wang, Yuji , Ni, Su , Wang, Jiahao , Zhao, Chenyu , Xu, Chao

Mayo Clinic

No container title available | July 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3175974/v1 Get It

Abstract Background Osteoarthritis (OA) is one of the most common degenerative diseases. Accumulating evidence suggests that ferroptosis may be important in the progression of OA. Angelica Sinensis polysaccharide (ASP), a traditional Chinese medicine, possesses antioxidative, anti-inflammatory and anti-apoptotic properties. However, it is unclear whether ASP can slow down the progression of osteoarthritis by suppressing ferroptosis. Methods Collection of postoperative joint cartilage from patients who underwent total knee arthroplasty (TKA), detection of ferroptosis-related markers including glutathione peroxidase 4 (GPX4) and ferritin heavy polypeptide 1 (FTH1) expression, as well as glutathione (GSH) and malondialdehyde (MDA) levels, and investigation of the correlation between ferroptosis and osteoarthritis. Chondrocytes were isolated and cultured, stimulated separately with IL-1β or erastin, rescued by ASP and ferroptosis inhibitors, and changes in cell viability and ferroptosis were detected. A destabilization of the medial meniscus surgical model (DMM) model was established in mice, and ASP was administered orally at different dosages to evaluate its therapeutic effect and level of ferroptosis. Results First, the expression of GPX4, FTH1 and reduced GSH was lower while the MDA level was up-regulated in cartilage of the OA group as compared to the control group. Moreover, chondrocyte ferroptosis induced by Erastin or IL-1β was rescued by the application of ASP or ferroptosis inhibitors in vitro. Further, the anti-ferroptotic effect of ASP was related to enhanced nuclear transfer of Nrf2 and decreased activation of NF-κB as indicated by down-regulated expression of p-p65. Next, the in vivo experiments showed that ASP alleviated the cartilage damage of mice joints induced by DMM. Conclusions In summary, ASP can attenuate chondrocyte ferroptosis through the Nrf2/NF-κB pathway in the progression of OA, suggesting that ASP may a potential inhibitor of ferroptosis for the treatment of OA.